An overview of likely lab audit targets for the coming year, and how laboratories can ensure they’re prepared.
Recent advisory opinion offers insight on how healthcare providers may want to structure arrangements involving online directories.
Inadequate CMS oversight resulted in $888.2 million in improper payments for the highest reimbursing molecular pathology genetic tests, report says.
Though UDT-related enforcement actions predominate, an uncommon vendor-related case was in the mix this month.
These three lab testing areas were the main sources of fraud and abuse revealed in the OIG’s latest Semi-Annual Report to Congress.